Issue Author Elias Jabbour, MD Assistant Professor Leukemia Department MD Anderson Cancer Center Houston, TX
Series Co-contributors Mikkael A. Sekeres, MD, MS Professor of Medicine Director, Leukemia Program Cleveland Clinic Taussig Cancer Institute Cleveland, OH
B. Douglas Smith, MD Associate Professor of Oncology Division of Hematologic Malignancies Sidney Kimmel Cancer Center at Johns Hopkins Baltimore, MD
CCME Reviewer Victor B. Hatcher, PhD Professor of Medicine and Biochemistry Associate Dean, CME and Research Albert Einstein College of Medicine Director of the Office of Research and Sponsored Programs Director of CME Montefiore Medical Center Bronx, NY
AMA PRA Category 1 Credit TM Medium
A CME-certified interactive newsletter series on the management of acute myeloid leukemia (AML).
Acute myeloid leukemia is a rapidly progressing cancer that starts in the bone marrow. AML can progress quickly without treatment; however, rates of remission and cure have increased over the past few decades as evidence for optimal therapeutic regimens has emerged. Cytogenetics and mutational gene profiling support a risk-stratification approach to AML treatment. A better understanding of molecular biology and mutations in AML is leading to the development of targeted therapies to improve clinical outcomes in subsets of AML. Deregulated cell cycle control contributes to increased proliferation in AML, and a better understanding of cell cycle regulation and deregulation has led to new AML therapeutic strategies.
The goal of this activity is to increase knowledge and competency among hematology-oncology clinicians, ultimately improving complete remission rate and overall survival in their patients with AML. Program Developer/Facilitator
This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.
This activity is intended for hematologists, oncologists, and other clinicians involved in the management of AML.
Upon completion of this educational activity, the participant should be able to:
Identify patients with AML who may benefit from non-intensive therapy.
Describe established and investigational therapeutic options for AML patients ineligible for intensive therapy.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine and MCM Education staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product not yet approved for use in the United States.
Dr. Sekeres discloses that he has served as a consultant for Celgene and Amgen.
Dr. Smith has no relevant financial disclosures.
Dr. Jabbour has no relevant financial disclosures.
The Staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine and Montefiore Medical Center have no relevant financial disclosures.
Dr. Hatcher has no relevant financial disclosures.
Don Harting (Medical Writer) has no relevant financial disclosures.
Kathleen Hines (MCM Education Editorial Director) has no relevant financial disclosures. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership by Albert Einstein College of Medicine, Montefiore Medical Center and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 75% or better on the post-test.
This activity will take approximately 30 minutes to complete. Commercial Support Statements
Supported by independent educational grants from Boehringer Ingelheim, Inc. and Celgene.
There are no fees for participating in or receiving credit for this online educational activity.
This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online. Be sure to review both written and audio/slide content.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, Boehringer Ingelheim, Inc., or Celgene. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.